Home Self Admin denied for failing step therapy by Humana?

Humana's specific coverage criteria for home self admin are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Step Therapy Before Home Self-Administration — and How to Appeal

A step-therapy denial for home self-administration means Humana requires documented evidence that the patient first received the drug or a comparable therapy through a different, plan-preferred channel — most commonly in a facility or infusion center — before approving coverage for the home self-administration route. The plan's rationale is typically that facility administration allows clinical monitoring; the step-therapy rule is a way of establishing clinical stability before transitioning to home use.

### Why This Denial Is Appealable

Step-therapy requirements for an administration route — as distinct from step therapy for a drug class — are particularly contestable when the prescriber has documented a clinical reason why the patient cannot or should not complete the required facility-based step. Step-therapy override protections (enacted in many states and available under Humana's own exception policy) apply when the required step is contraindicated, has been tried and failed, would cause foreseeable harm, or when delaying the home-administration route would adversely affect the patient's health. The appeal should also challenge any requirement that the patient restart a step already completed, which is a common source of inappropriate denials.

### Federal Appeal Rights

• Step-therapy exception request: File a formal step-therapy exception request alongside or before the internal appeal. Humana is required to respond within defined timeframes.
• Internal appeal: File within the timeframe on the denial notice. Humana must decide within 30 days for standard pre-service appeals.
• External review (ACA §2719 / ERISA §503): After a final internal denial, you have independent external review rights, generally within four months. External reviewers apply generally accepted medical standards, not just the plan's internal step protocols.
• Expedited review: Request this if delaying home self-administration would seriously jeopardize health; decisions typically required within 72 hours.

### Documentation to Gather

1. Facility-administration history: Records of any prior facility-based or infusion-center administration, including dates, outcomes, and the prescriber's decision to transition to home use. 2. Reason for step completion or bypass: If the required step was completed, document it thoroughly. If the required step was never attempted because it is clinically inappropriate, document the clinical reason. 3. Prescriber step-therapy exception letter: A letter from the treating physician explaining why the required step has been satisfied or why an exception applies — specifically addressing Humana's stated step-therapy criteria. 4. Clinical-stability documentation: Chart notes confirming the patient is clinically appropriate for home self-administration (trained, adherent, stable). 5. Home-administration training records: Evidence of patient training, supporting the clinical appropriateness of the transition.

### Criteria-Mapping Structure

Obtain Humana's step-therapy criteria for home self-administration of the relevant drug from their published coverage policy. List each step requirement. For each one, provide the chart evidence that the step was completed, or the clinical documentation supporting an exception. Do not leave any step unanswered — an incomplete response is the most common reason step-therapy appeals fail.

Always verify current step-therapy requirements against Humana's published policy and the FDA-approved prescribing label.